Get started
ReutersReuters

Briacell Therapeutics’ Subsidiary, BriaPro, Files Patent Application For Immuno-Oncology Platform With Novel Multitargeting Agents

RefinitivLess than 1 min read
BCT

Briacell Therapeutics Corp BCT:

  • BRIACELL’S SUBSIDIARY, BRIAPRO, FILES PATENT APPLICATION FOR IMMUNO-ONCOLOGY PLATFORM WITH NOVEL MULTITARGETING AGENTS

Canadian stocksNorth AmericaReutersUS stocks
refinitivrefinitiv
© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html
Login or create a forever free account to read this news

More news from Reuters